RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA

被引:396
|
作者
HEHLMANN, R [1 ]
HEIMPEL, H [1 ]
HASFORD, J [1 ]
KOLB, HJ [1 ]
PRALLE, H [1 ]
HOSSFELD, DK [1 ]
QUEISSER, W [1 ]
LOFFLER, H [1 ]
HOCHHAUS, A [1 ]
HEINZE, B [1 ]
GEORGII, A [1 ]
BARTRAM, CR [1 ]
GRIESSHAMMER, M [1 ]
BERGMANN, L [1 ]
ESSERS, U [1 ]
FALGE, C [1 ]
QUEISSER, U [1 ]
MEYER, P [1 ]
SCHMITZ, N [1 ]
EIMERMACHER, H [1 ]
WALTHER, F [1 ]
FETT, W [1 ]
KLEEBERG, UR [1 ]
KABISCH, A [1 ]
NERL, C [1 ]
ZIMMERMANN, R [1 ]
MEURET, G [1 ]
TICHELLI, A [1 ]
KANZ, L [1 ]
TIGGES, FJ [1 ]
SCHMID, L [1 ]
BROCKHAUS, W [1 ]
TOBLER, A [1 ]
REITER, A [1 ]
PERKER, M [1 ]
EMMERICH, B [1 ]
VERPOORT, K [1 ]
ZANKOVICH, R [1 ]
VONWUSSOW, P [1 ]
PRUMMER, O [1 ]
THIELE, J [1 ]
BUHR, T [1 ]
CARBONELL, F [1 ]
ANSARI, H [1 ]
机构
[1] UNIV HEIDELBERG, KLINIKUM MANNHEIM, MANNHEIM, GERMANY
关键词
D O I
10.1182/blood.V84.12.4064.bloodjournal84124064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As curative bone marrow transplantation is available only to a minority of patients with chronic myelogenous leukemia (CML), drug therapy remains of central interest. Several nonrandomized studies have suggested that interferon-alpha (IFN) may prolong survival in CML. In a randomized multicenter study the influence of IFN versus busulfan or hydroxyurea (HU) on survival of Philadelphia-positive (Ph+) CML was examined. A total of 513 Ph+ patients were randomized for treatment as follows: 133 for IFN, 186 for busulfan, and 194 for HU. IFN-treated CML patients have a significant survival advantage over busulfan-treated (P = .008), but not over HU-treated patients (P = .44). The longer survival is due to slower progression to blast crisis. Median survival of IFN-treated patients is 5.5 years [5-year survival, 59%; 95% confidence interval (CI), 48%-70%], of busulfan-treated patients, 3.8 years (5-year survival, 32%; CI, 24%-40%), and of HU-treated patients, 4.7 years (5-year survival, 44%; CI, 36%-53%). Patients who continue on IFN survive longer than those in whom IFN is discontinued before blast crisis (P = .007). Complete hematologic IFN-responders have a survival advantage over partial responders or nonresponders (P = .02). Cytogenetic IFN-responders have no significant survival advantage over nonresponders (P = .2). Patients who attain white blood cell (WBC) counts of 10 x 10(9)/L or less have a survival advantage in the IFN (P = .007) and HU (P = .05) groups. Whereas toxicity in the IFN group was considerably higher than in the busulfan or HU groups, long-lasting cytopenias necessitating discontinuation of therapy as observed with busulfan have not been seen with IFN or HU. The problems of conventional prognostic scores (Sokal's score, Score 1) that we observed in IFN-treated patients support the idea that IFN changes the natural course of CML. We conclude that, with regard to survival of CML in the chronic phase, IFN is superior to busulfan and as effective as HU. Whether and to what extent IFN is superior to HU appears to depend, at least in part, on the degree of WBC suppression by HU-therapy and on the risk profile of the patients. (C) 1994 by The American Society of Hematology.
引用
收藏
页码:4064 / 4077
页数:14
相关论文
共 50 条
  • [31] Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia
    M Wilhelm
    C Bueso-Ramos
    S O’Brien
    S Pierce
    M Keating
    M Talpaz
    HM Kantarjian
    Leukemia, 1998, 12 : 65 - 70
  • [32] ACUTE-PANCREATITIS ASSOCIATED WITH INTERFERON-ALPHA THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA
    SOTOMATSU, M
    SHIMODA, M
    OGAWA, C
    MORIKAWA, A
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 48 (03) : 211 - 212
  • [33] THERAPEUTIC PROGRESS AND COMPARATIVE ASPECTS IN CHRONIC MYELOGENOUS LEUKEMIA (CML) - INTERFERON-ALPHA VS HYDROXYUREA VS BUSULFAN AND EXPRESSION OF MMTV-RELATED ENDOGENOUS RETROVIRAL SEQUENCES IN CML
    HEHLMANN, R
    KISTER, P
    WILLER, A
    SIMON, M
    SCHENK, M
    SEIFARTH, W
    PAPAKONSTANTINOU, G
    SAUSSELE, S
    KOLB, HJ
    ANSARI, H
    LEIBMOSCH, C
    LEUKEMIA, 1994, 8 : S127 - S132
  • [34] Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia
    J Cortes
    L Fayad
    H Kantarjian
    S O’Brien
    M-S Lee
    M Talpaz
    Leukemia, 1998, 12 : 455 - 462
  • [35] Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia
    Kattan, MW
    Inoue, Y
    Giles, FJ
    Talpaz, M
    Ozer, H
    Guilhot, F
    Zuffa, E
    Huber, SL
    Beck, JR
    ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) : 541 - +
  • [36] Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia
    Cortes, J
    Fayad, L
    Kantarjian, H
    O'Brien, S
    Lee, MS
    Talpaz, M
    LEUKEMIA, 1998, 12 (04) : 455 - 462
  • [37] INTERFERON-ALPHA THERAPY DURING PREGNANCY IN CHRONIC MYELOGENOUS LEUKEMIA AND HAIRY-CELL LEUKEMIA
    BAER, MR
    OZER, H
    FOON, KA
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (02) : 167 - 169
  • [38] Cost-effectiveness of interferon-alpha as maintenance therapy in chronic myelogenous leukemia - Response
    Kattan, MW
    Beck, JR
    ANNALS OF INTERNAL MEDICINE, 1997, 126 (08) : 664 - 665
  • [39] HEMOLYTIC-UREMIC SYNDROME IN A PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH INTERFERON-ALPHA
    SCHLAIFER, D
    DUMAZER, P
    SPENATTO, N
    MIGNONCONTE, M
    BROUSSET, P
    LUMBROSO, C
    COOPER, M
    MULLER, C
    HUGUET, F
    ATTAL, M
    LAURENT, G
    PRIS, J
    AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (03) : 254 - 255
  • [40] Proposal of a scoring system for responsiveness to interferon-alpha at diagnosis in chronic myelogenous leukemia.
    Dascalescu, CM
    Chomel, JC
    Bouilly, I
    Chauvet, M
    Sotto, MF
    Guilhot, J
    Rivet, J
    Sotto, JJ
    Kitzis, A
    Guilhot, F
    BLOOD, 1997, 90 (10) : 3988 - 3988